Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. reported that Chief Commercial Officer Mark Hopman received an employee stock option grant covering 91,520 shares of common stock. The option has an exercise price of $12.63 per share and expires on February 26, 2036.
The award was granted at no cost on the grant date and vests in 36 equal monthly installments starting on March 1, 2026, reflecting a long-term equity compensation arrangement rather than an open-market share purchase or sale.
Beta Bionics, Inc. reported that Chief Financial Officer Stephen Feider received a grant of employee stock options covering 110,342 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036.
The grant was awarded as compensation and did not involve any open-market buying or selling. According to the terms, the options vest in 36 equal monthly installments starting on March 1, 2026, meaning the CFO earns the right to exercise them gradually over three years.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 353 shares of common stock in an open-market transaction on March 4, 2026. The shares were sold at an average price of $11.57 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 13, 2025.
After this sale, Hopman directly owned 139,133 shares of Beta Bionics common stock. The filing characterizes the transaction as an open-market sale, and the trading plan structure indicates it was executed under a pre-established schedule rather than at the insider’s discretion on the trade date.
BBNX submitted a Rule 144 notice listing a proposed sale of 353 common shares issued as an equity award, with a transaction date shown as 03/01/2026 and cash as the consideration. The filing also reports prior sales of 2,061 common shares by Mark Hopman on 12/04/2025 for $63,192.28.
Michael Mensinger reported proposed sales of Common Stock on Form 144 relating to equity received for services to the issuer. The filing lists securities vested as Restricted Stock Units on 03/01/2026 and shows multiple sales in the past three months.
The filing records sales of 1,063 shares on 12/02/2025, 7,200 shares on 01/02/2026, 600 shares on 01/02/2026, and 2,200 shares on 01/06/2026, with amounts shown alongside each entry.
Stephen Feider submitted a Form 144 notice reporting proposed sales of Common Stock tied to Beta Bionics, Inc./BBNX. The filing lists Restricted Stock Units vesting under a registered plan dated 03/01/2026 and shows prior sale entries dated 12/02/2025 and 01/02/2026.
Sean Saint reported a Form 144 sale notice relating to Common Stock of Beta Bionics, Inc. The filing lists 3,384 shares associated with restricted stock units vesting under a registered plan on 03/01/2026, with Morgan Stanley Smith Barney LLC named as broker on 03/02/2026.
The filing also shows prior sales of 3,278 shares on 12/02/2025 for $96,163.08. The securities are described as compensation for services rendered to the issuer.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported new equity awards and a small share sale. He received a grant of 109,105 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan and 58,749 stock options, which vest in 36 equal monthly installments starting on March 1, 2026.
On March 2, 2026, he sold 834 shares of common stock in an open-market transaction at a weighted average price of $12.3616, in a price range between $12.20 and $12.55, to cover tax withholding obligations tied to restricted stock unit vesting. After this sale, he directly owned 139,486 shares of common stock.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported multiple equity transactions. He sold 1,026 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share, with prices ranging from $12.20 to $12.55, to cover tax withholding obligations from vesting restricted stock units.
He also acquired 109,105 shares of common stock as a grant classified as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. In addition, he received an employee stock option covering 58,749 shares, which is scheduled to vest in 36 equal monthly installments starting from March 1, 2026.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a mix of equity grants and a small share sale. On February 27, 2026, he received a grant of 58,749 employee stock options and 109,105 shares of common stock at a price of $0.0000 per share, including a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The option award will vest in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,064 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share to cover tax withholding obligations associated with restricted stock unit vesting, leaving him with 188,793 common shares directly held after that sale.